Mark Anthony Mccamish - Net Worth and Insider Trading
Mark Anthony Mccamish Net Worth
The estimated net worth of Mark Anthony Mccamish is at least $1 Million dollars as of 2024-12-26. Mark Anthony Mccamish is the Director of Avadel Pharmaceuticals PLC and owns about 67,025 shares of Avadel Pharmaceuticals PLC (AVDL) stock worth over $696,725. Mark Anthony Mccamish is also the President and CEO of Forty Seven Inc and owns about 4,595 shares of Forty Seven Inc (FTSV) stock worth over $438,868. Details can be seen in Mark Anthony Mccamish's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Anthony Mccamish has not made any transactions after 2023-12-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark Anthony Mccamish
Mark Anthony Mccamish Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Anthony Mccamish owns 4 companies in total, including Avadel Pharmaceuticals PLC (AVDL) , Rafael Holdings Inc (RFL) , and LifeSci Acquisition Corp (LSACU) among others .
Click here to see the complete history of Mark Anthony Mccamish’s form 4 insider trades.
Insider Ownership Summary of Mark Anthony Mccamish
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
AVDL | Avadel Pharmaceuticals PLC | 2023-12-28 | director |
RFL | Rafael Holdings Inc | 2021-06-14 | director |
LSACU | LifeSci Acquisition Corp | 2020-12-23 | director |
2020-12-23 | director |
Mark Anthony Mccamish Latest Holdings Summary
Mark Anthony Mccamish currently owns a total of 2 stocks. Among these stocks, Mark Anthony Mccamish owns 67,025 shares of Avadel Pharmaceuticals PLC (AVDL) as of December 28, 2023, with a value of $696,725 and a weighting of 61.35%. Mark Anthony Mccamish also owns 4,595 shares of Forty Seven Inc (FTSV) as of April 1, 2020, with a value of $438,868 and a weighting of 38.65%.
Latest Holdings of Mark Anthony Mccamish
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
AVDL | Avadel Pharmaceuticals PLC | 2023-12-28 | 67,025 | 10.40 | 696,725 |
FTSV | Forty Seven Inc | 2020-04-01 | 4,595 | 95.51 | 438,868 |
Holding Weightings of Mark Anthony Mccamish
Mark Anthony Mccamish Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Anthony Mccamish has made a total of 3 transactions in Avadel Pharmaceuticals PLC (AVDL) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Avadel Pharmaceuticals PLC is the sale of 75,000 shares on December 28, 2023, which brought Mark Anthony Mccamish around $1 Million.
According to the SEC Form 4 filings, Mark Anthony Mccamish has made a total of 1 transactions in Forty Seven Inc (FTSV) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Forty Seven Inc is the sale of 32,577 shares on April 1, 2020, which brought Mark Anthony Mccamish around $3 Million.
Insider Trading History of Mark Anthony Mccamish
- 1
Mark Anthony Mccamish Trading Performance
GuruFocus tracks the stock performance after each of Mark Anthony Mccamish's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Anthony Mccamish is 29.78%. GuruFocus also compares Mark Anthony Mccamish's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Anthony Mccamish within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Anthony Mccamish's insider trading performs compared to the benchmark.
Performance of Mark Anthony Mccamish
Mark Anthony Mccamish Ownership Network
Mark Anthony Mccamish Owned Company Details
What does Avadel Pharmaceuticals PLC do?
Who are the key executives at Avadel Pharmaceuticals PLC?
Mark Anthony Mccamish is the director of Avadel Pharmaceuticals PLC. Other key executives at Avadel Pharmaceuticals PLC include Chief Financial Officer Thomas S Mchugh , director & Chief Executive Officer Greg J Divis , and Chief Commercial Officer Richard J Kim .
Avadel Pharmaceuticals PLC (AVDL) Insider Trades Summary
Over the past 18 months, Mark Anthony Mccamish made 2 insider transaction in Avadel Pharmaceuticals PLC (AVDL) with a net sale of 103,975. Other recent insider transactions involving Avadel Pharmaceuticals PLC (AVDL) include a net purchase of 11,300 shares made by Thomas S Mchugh , a net purchase of 34,279 shares made by Geoffrey Michael Glass , and a net purchase of 20,000 shares made by Greg J Divis .
In summary, during the past 3 months, insiders sold 0 shares of Avadel Pharmaceuticals PLC (AVDL) in total and bought 40,579 shares, with a net purchase of 40,579 shares. During the past 18 months, 103,975 shares of Avadel Pharmaceuticals PLC (AVDL) were sold and 68,579 shares were bought by its insiders, resulting in a net sale of 35,396 shares.
Avadel Pharmaceuticals PLC (AVDL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Avadel Pharmaceuticals PLC Insider Transactions
Mark Anthony Mccamish Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Anthony Mccamish. You might contact Mark Anthony Mccamish via mailing address: C/o Forty Seven, Inc., 1490 O'brien Drive, Suite A, Menlo Park Ca 94025.